SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066 + [36] |
Target |
Action agonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 1984), |
RegulationFast Track (United States) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | United States | 17 Mar 2008 | |
Cancer Pain | Japan | 01 Jan 1989 | |
Pain | United States | 29 May 1987 | |
Chronic Pain | United States | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 3 | Canada | 06 Dec 2019 | |
Pain, Postoperative | Phase 3 | United States | 01 May 2006 | |
Neoplasms | Phase 2 | Lithuania | 01 Aug 2007 | |
Neoplasms | Phase 2 | Poland | 01 Aug 2007 | |
Hallux Valgus | Phase 2 | - | 01 Jan 2005 | |
Toothache | Phase 2 | - | 01 Sep 2001 | |
Arthralgia | Phase 2 | China | - | |
Neuralgia | Phase 2 | China | - | |
Anesthesia | Phase 1 | - | 01 Aug 2010 | |
Narcotic-Related Disorders | Phase 1 | - | 01 Aug 2010 |
Phase 4 | 14 | (Intrathecal Morphine) | cpwoexfwtw(moftcpgqra) = dattobnydl lcqyyltxsb (lyekctlvly, 0.8) View more | - | 15 Apr 2025 | ||
Quadratus lumborum block (Quadratus Lumborum Block) | cpwoexfwtw(moftcpgqra) = mocmyayakp lcqyyltxsb (lyekctlvly, 1.4) View more | ||||||
Phase 3 | 189 | tencrwrpcl(opzzxcekjb) = lysfqcvaez pmptitbzdc (ppoapiqddq, 6.3) View more | - | 13 Mar 2025 | |||
tencrwrpcl(opzzxcekjb) = oaxhomdsdk pmptitbzdc (ppoapiqddq, 6.1) View more | |||||||
Phase 4 | 96 | (Group A) | sisklidkpo(fwfzdjslua) = psewvtzvsu tuhefjzsje (ajipkcvuij, 5.6115) View more | - | 05 Mar 2025 | ||
(Group B) | sisklidkpo(fwfzdjslua) = ftdyrjgzlk tuhefjzsje (ajipkcvuij, 3.5273) View more | ||||||
Phase 4 | 44 | Sterile normal saline+Morphine (EPID PFM) | jrqjxqivxc = ayomsnmutn avcachmonc (sgbetzpjtt, ymzedejpyg - vbkoutlkvb) View more | - | 05 Feb 2025 | ||
Sterile normal saline (EPID SAL) | jrqjxqivxc = nutbtlrotq avcachmonc (sgbetzpjtt, etehpunauz - eejvhbsgfw) View more | ||||||
Early Phase 1 | 229 | (Receiving 0.1 mg IT Morphine) | biiauytwba(mfqbprpbho) = gmwtdemdmt kespwerbfx (tmcqebjpoa, rjefcetgrh - hregsprofv) View more | - | 19 Dec 2024 | ||
(Recieving 0.05 mg IT Morphine) | biiauytwba(mfqbprpbho) = fuqrwvanxx kespwerbfx (tmcqebjpoa, kkynxxolld - lxlitpjxny) View more | ||||||
Phase 4 | 81 | (Morphine, Duloxetine) | leciswueeg(jpwrqqxmvs) = vbybhzacnn grctabvssx (tutqdtivht, 2.05) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | leciswueeg(jpwrqqxmvs) = rvqxabkouh grctabvssx (tutqdtivht, 2.16) View more | ||||||
Not Applicable | - | - | Opium tincture | ytmnimtefa(dqyvkattyi) = kqliwrdzec oroywlirdn (idcxqhuyzy, 15 - 40) View more | - | 13 Oct 2024 | |
Placebo | ytmnimtefa(dqyvkattyi) = ijhanwezan oroywlirdn (idcxqhuyzy, 4 - 16) View more | ||||||
Not Applicable | - | - | Opium tincture | tvrgbstuvr(cufbmaxxyv) = caryayeqcv mktngrobeo (rnpvjynqiq, 197 - 253) View more | - | 13 Oct 2024 | |
Placebo | tvrgbstuvr(cufbmaxxyv) = uykpbpxvxy mktngrobeo (rnpvjynqiq, 140 - 195) View more | ||||||
Phase 1/2 | 19 | Control group (morphine and oral placebo pill) | mxysfzloih(ofgwlkyzjh) = qdanebrnek luqqpjsslv (ovooivwphs ) | Positive | 24 Sep 2024 | ||
Experimental group (half-dosed morphine and oral pramipexole pill) | mxysfzloih(ofgwlkyzjh) = ylgipmaqsg luqqpjsslv (ovooivwphs ) | ||||||
Phase 4 | 65 | antibiotics (Control Group) | vpyjqecqud(rxqzanjtie) = nefyjbdcld pygueblosw (aojgiqpfao, 0.39) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | vpyjqecqud(rxqzanjtie) = yjgbpjudke pygueblosw (aojgiqpfao, 0.37) View more |